Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single
Ascending Doses of MEDI5117 (anti-IL-6)

Inclusion Criteria:

- Active Rheumatoid Arthritis (RA) for 6 months or more.

- Males or nonpregnant, nonlactating femails aged 20 to 75 years, inclusive.

- Body Mass Index (BMI) between 19 and 36 kg/m2 and weight between 50 and 145 kg,
inclusive.

- Males, unless surgically sterile, must use 2 effective methods of birth control from
Day 1 through follow-up.

Exclusion Criteria:

- History or presence of any clinically significant disease or disorder which has not
been stable over the previous 3 months.

- History of liver disease, bilirubin elevations, or Gilbert's Syndrome.

- Any systematic inflammatory condition in addition to RA (polymyalgia rheumatica,
giant cell arthritis, systemic lupus, gout, pyrophosphate arthropathy).

- Current, chronic pain disorders including fibromyalgia and chronic regional pain
syndromes or chronic fatigue syndromes.

- Intramuscular steroid injection or intraarticular steroid injection within 1 month of
enrollment.